HRA Pharma started recruiting in April for an actual use trial, using oral contraceptives with norgestrel 0.075 mg, and expects to complete its study in April 2019, according to clinicaltrials.gov's database. Advocacy group Ibis Reproductive Health, which is working with HRA on an NDA for an OTC oral contraceptive, called the start of the study a "pivotal moment" in moving birth control drugs out of Rx-only.
Recruiting has started for a 900-subject study that could be a key to submitting a new drug application to US FDA for making a daily oral contraceptive available OTC.
HRA Pharma SA started recruiting in April for an actual use trial, using progestin-only oral contraceptives with norgestrel 0.075...